Skip to main content
NCBI home page
BMC Medical Genomics logoLink to BMC Medical Genomics
. 2023 Apr 7;16:76. doi: 10.1186/s12920-023-01497-9

Sleep traits and risk of end-stage renal disease: a mendelian randomization study

Kaixin Li 1, Jiaxi Zhao 2, Wenjing Yang 3, Zhibin Ye 1,✉
PMCID: PMC10080763  PMID: 37029366

Abstract

Background

Epidemiological evidence relating sleep disorders to end-stage renal disease (ESRD) has been obscure. The present study is sought to examine the association between sleep traits and ESRD.

Methods

For this analysis, we selected genetic instruments for sleep traits from published genome-wide association studies (GWAS). As instrumental variables, independent genetic variations linked with seven sleep-related features (sleep duration, getting up in the morning, daytime napping, chronotype of morning/evening person, sleeplessness/insomnia, non-snoring, and daytime dozing) were chosen. A two-sample Mendelian randomization (TSMR) study was conducted to assess the causal relationship between sleep traits and ESRD (N = 33,061). The reverse MR analysis subsequently determined the causal relationship between ESRD and sleep traits. The causal effects were estimated using inverse variance weighted, MR-Egger, weighted median. To conduct sensitivity studies, Cochran’s Q test, MR-Egger intercept test, MR-PRESSO, leave-one-out analysis, and funnel plot were used. To study the potential mediators, multivariable mendelian randomization analyses were undertaken further.

Results

Genetically predicted sleeplessness/ insomnia (OR = 6.11, 95%CI 1.00-37.3, P = 0.049, FDR = 0.105), getting up in the morning easily(OR = 0.23, 95%CI 0.063–0.85; P = 0.0278, FDR = 0.105), non-snoring (OR = 4.76E-02, 95%CI 2.29E-03-0.985, P = 0.0488, FDR = 0.105) was suggestively associated with the risk of ESRD. However, we found no evidence favoring a causal association between other sleep traits and ESRD through the IVW method.

Conclusion

The present TSMR found no strong evidence of a bidirectional causal association between genetically predicted sleep traits and ESRD.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12920-023-01497-9.

Keywords: Mendelian randomization, End-stage renal disease, Sleep traits, Insomnia, Snoring

Introduction

Chronic kidney disease (CKD) is an international health issue [1]. A considerable number of CKD patients will progress to end-stage renal disease (ESRD) [2]. Therefore, finding preventative strategies for ESRD is especially important. Previous epidemiological studies have pointed out some potential risk factors to increase the incidence of ESRD. Significant roles are played by diabetes, hypertension, and obesity in the development of ESRD [3]. However, the etiology of ESRD remains obscure. Exploring the pathophysiology of ESRD aids in developing preventative and therapeutic measures.

The prevalence of sleep problems in patients with CKD has been shown to be significant, with roughly 50% of patients suffering from poor sleep quality or insomnia [4], and 44% of patients with ESRD experiencing sleep disturbance [5]. Several studies indicated that sleep was one of the potential risk factors for the development and progression of CKD [6, 7]. A prospective cohort study found that individuals with poor sleep habits had an elevated risk of CKD [7]. In addition, sleep disorder is frequently linked to obesity [8, 9], metabolic syndrome [10], diabetes [11], and hypertension [12], all of which hasten the progression of renal disease [13]. A cohort study identified poor sleep quality as a predictor of ESRD and found that both short (5 h) and long (8 h) sleep duration were linked to the risk of ESRD [6]. However, researchers were unable to determine if sleep disruption raises the risk of ESRD.

Mendelian randomization (MR) analysis uses genetic variants as instrumental variables (IVs) for exposure, which reduces measurement error and bias. MR is used to test exposure-outcome causal inferences. Two-sample MR (TSMR) allows IV analysis when the exposure and the outcome variables are measured in two independent datasets, so this approach can be particularly valuable when applied to large datasets that exist relating GWAS data to disease outcomes, but which lack intermediate phenotype data [14]. We conducted a TSMR research to examine the causative influence of seven sleep traits on ESRD.

Methods

Study design

Figure 1 shows the overview of the study design. We conducted a bidirectional MR analysis to assess sleep traits’ association with ESRD. Setting dialysis and glomerular filtration rate as additional outcomes to supplement results, and then we conducted multivariable MR to test the true causal association between sleep traits and ESRD. All statistical analyses were performed using the two-sample MR package (version 0.5.6) [15] and MR-PRESSO package (version 1.0) [16] in R (version 4.2.1). The study methods were compliant with the STROBE-MR checklist [17] (Supplementary Tables 12, Additional File 1).

Fig. 1.

Fig. 1

Open in a new tab

Overview of study design. BMI indicates body mass index; ESRD, End-stage renal disease; GWAS genome-wide associations study; IVW inverse-variance weighted; SNP single-nucleotide polymorphisms. Data extracted were beta coefficients with corresponding standard errors of the SNP-insomnia, SNP-getting up in the morning, SNP-non-snoring, SNP-sleep duration, SNP- morning chronotype, SNP-napping during the day, SNP-daytime dozing, SNP-ESRD, SNP-dialysis, SNP-glomerular filtration rate, SNP-depression, SNP-BMI, SNP-hypertension and SNP-diabetes associations

Data sources

Sleep-related characteristics and outcome data sources have been gathered and made accessible online, an additional file shows this in more detail (see Supplementary Tables 1, Additional File 1). Since this study was based on published data, no ethical approval nor informed consent was required.

Exposures

Summary statistics from IEU open GWAS project were used as the data for sleep traits [18], which included 337000 unrelated individuals aged from 40 to 69 years old from a study of UK Biobank between 2006–2010 [19]. Instrumental Variables (IVs) were chosen from previously known single-nucleotide polymorphisms (SNPs) related to each sleep trait (exposure). Insomnia was characterized as difficulty falling asleep at night or waking up in the middle of the night. Getting up in the morning was evaluated based on how easy it was to locate, and the significant self-report was fairly easy. The genetic connection to non-snoring was based on snoring complaints from a partner, relative, or friend. The genetic relationship of sleep duration was determined by asking people how many hours they slept per day, and the units of measurement were hours per day. Chronotype is the natural propensity for the individual to sleep at a particular time, and the morning chronotype is someone who self-reported as more of a ‘morning’ person than an ‘evening’ person.

Outcome

Summary statistics for ESRD were downloaded from the NHGRI-EBI GWAS Catalog (Buniello, MacArthur, et al., 2019) for study GCST008031 (Wojcik GL et al. 2019) downloaded on 01/09/2022. ESRD was defined as an eGFR (by the CKD-Epi Equation) of < = 15 ml/min/1.73m2. ESRD was modeled as a binary outcome, and models were adjusted for age, sex, race/ethnicity, study, and study center, etc. The study comprised 33,061 individuals, including 602 cases and 32,459 controls [20]. The summary statistics for glomerular filtration rate (GFR) were downloaded from the NHGRI-EBI GWAS Catalog (Buniello, MacArthur, et al., 2019) on 17/12/2022 for study (GCST003375) including 32,834 European ancestry individuals. The assessment of GFR was based on cystatin C, and GFRcys was estimated as 76.7 × (serum cystatin C)−1.19 [21]. The outcome summary statistics for dialysis were obtained from the 5th release of the FinnGen study with 648 cases and 212,841 controls [22].

Risk factors

Summary statistics for diabetes were downloaded from the NHGRI-EBI GWAS Catalog (Buniello, MacArthur, et al., 2019) for study GCST006867 downloaded on 17/12/2022 [23]. The summary statistics for depression and hypertension were obtained from the 5th release of the FinnGen study [22]. Genetic instrumental variables for BMI were obtained from the Genetic Investigation of Anthropometric Traits (GIANT) Consortium via the IEU Open GWAS [15].

Selection of instrumental variables

To determine the optimal IVs for sleep, we first extracted SNPs from published data strongly associated with sleep traits (p < 5 × 10− 8). Linkage disequilibrium (LD) SNPs were eliminated (r2 0.001, clumping window = 10,000 kb) to ensure exposure instrument independence. Then, we extracted the sleep trait instrumental factors from the ESRD GWAS and eliminated palindromic SNPs. After harmonizing exposure and outcome data, we discovered that the same allele affects both exposure and outcome. Last, we filtered SNPs with F-statistics greater than 10 to ensure instrument reliability and eliminate bias to satisfy the relevance assumption of MR analysis that genetic instruments were associated with the risk factor of interest. 28 SNPs for sleeplessness/insomnia, 37 for getting up in the morning, 22 for non-snoring, 44 for sleep duration, 80 for morning chronotype, 48 for napping during the day, and 18 for daytime dozing were extracted for MR analysis. The total F value for sleep duration, getting up in the morning, morning chronotype, napping during the day, insomnia, non-snoring, and daytime dozing were 660.15, 547.39, 1321.85, 935.98, 423.11, 334.99, and 315.36, respectively, and the phenotypic variation explained (PVE) for each exposure were 0.0019, 0.0016, 0.004, 0.0028, 0.0013, 0.0011, and 0.001, respectively. In the reverse MR analysis, a more relaxed threshold was used (p < 5 × 10− 6) to select more SNPs of ESRD, which had been previously used in MR research [24]. We extracted 23 SNP for ESRD with a total F-statistic of 124.05 and then removed the SNPs with F < 10 to satisfy the first MR assumption. Finally, we integrated 7 SNPs for ESRD. The PVE for ESRD was 0.23. The additional file (see Supplementary Tables 2–9, Additional File 1) provided an overview of GWAS datasets and related SNPs.

Mendelian randomization analysis

Using random-effects Inverse-variance weighted (IVW), MR Egger, and Weighted median, we examined if sleep traits caused ESRD risk. We chose IVW as the primary technique for MR analysis. In addition, false discovery rate (FDR) adjusted p-values proposed by Benjamini and Hochberg were used to address multiple correction testing [25]. An FDR lower than 0.05 indicated statistical significance and supported strong evidence of a causal relationship. Associations with p < 0.05 but FDR > 0.05 were regarded as suggestive evidence of association.

Sensitivity analysis

Cochran’s Q test, the MR-Egger regression test and the Mendelian Randomization Pleiotropy Residual Sum and Outlier (MR-PRESSO) test were used to identify heterogeneity or pleiotropy [16, 26, 27]. To check reproducibility, we ran a sensitivity analysis utilizing the leave-one-out technique.

Multivariable MR

To determine whether the genetic instruments were associated with the risk factor of interest, were independent of potential confounders, and could only affect the outcome through the risk factor and not through alternative pathways, we conducted multivariable MR using genetic variants associated with numerous, potentially connected exposures to estimate the effect of each exposure on a single outcome [28]. We included some risk factors as potential confounders in the sleep traits and ESRD relationship. The multivariable MR was applied to test whether there was a true causality between sleep traits and ESRD. Only causality suggested by the primary MR analysis would undergo further tests.

Results

Primary MR analysis for the association between sleep traits and ESRD

According to IVW analysis, there were suggestive associations between sleeplessness/ insomnia (OR = 6.11, 95%CI 1.00-37.3, P = 0.049, FDR = 0.105, Power = 0.95), Getting up easily in the morning (OR = 0.23, 95%CI 0.063–0.85; P = 0.0278, FDR = 0.105, Power = 0.1)(Fig. 4), non-snoring (OR 4.759E-02, 95%CI 2.29E-02–0.985, P = 0.0488, FDR = 0.105, Power = 0.12) and the risk of ESRD (Table 1). For other sleep behaviors, we found no evidence of associations between genetically-predicted sleep duration (OR = 0.622, 95%CI 0.158–2.447, P = 0.49, FDR = 0.686) (See Supplementary Fig. 1, Additional File 1), the morning chronotype (OR = 0.88, 95%CI 0.44–1.753, P = 0.73, FDR = 0.851) (See Supplementary Fig. 2, Additional File 1) and ESRD. Similarly, daytime dozing (0R = 1.2, 95%CI 4.48E-02–3.21E + 02, P = 0.91, FDR = 0.91) (See Supplementary Fig. 6, Additional File 1)and rarely daytime napping (OR = 4.15, 95%CI 0.93–18.44, P = 0.06, FDR = 0.105) (See Supplementary Fig. 3, Additional File 1) was not observed evidence of having a causal association with ESRD risk. (Figures 2 and 3).

Table 1.

The causal relationship between sleep traits and ESRD, dialysis and glomerualr filtration rate

Exposure Outcome IVW MR Egger Weighted median
OR/b 95%CI P FDR OR/b 95CI P OR/b 95CI P
Sleeplessness/insomnia ESRD 6.117 1.004-3.72e + 01 0.049 0.105 1038.81 0.007-1.63e + 08 0.26 4 0.324-4.92e + 01 0.28
Sleep duration 0.622 0.158–2.446 0.49 0.686 0.131 0.0005–37.97 0.48 1.81 0.275–11.917 0.53
Morning chronotype 0.889 0.447–1.767 0.73 0.8517 2.68 0.486–14.754 0.26 1.296 0.454–3.698 0.68
Getting up in the morning 0.232 0.063–0.853 0.028 0.105 1.16 0.027–50.53 0.938 0.166 0.027–1.015 0.051
Non-snoring 4.76E-02 2.3e-03-0.985 0.049 0.105 1.10E-06 2.22e-14-54.17 0.145 3.75E-02 5.03e-04-2.79 0.134
Daytime dozing 1.2 4.48d-02-3.21e + 01 0.91 0.91 831.7 1.94e-07-3.56e + 12 0.56 5.75 3.46e-02-3.14e + 02 0.607
Nap during the day 4.159 0.938–18.449 0.06 0.105 259.31 0.405-165921.23 0.099 7.06 0.846–58.93 0.07
ESRD Sleeplessness/insomnia 0.997 0.990–1.003 0.324 1.031 0.975–1.089 0.329 0.998 0.989–1.007 0.720
Sleep duration -0.001 -0.008-0.006 0.783 -0.022 -0.08-0.036 0.489 -0.002 -0.01-0.007 0.712
Morningchronotype 0.994 0.986–1.003 0.173 0.995 0.925–1.005 0.912 0.994 0.984–1.005 0.315
Getting up in the morning 1.002 0.995–1.008 0.616 0.981 0.926–1.039 0.539 1.001 0.992–1.009 0.862
Non-snoring 1.002 0.995–1.010 0.543 0.967 0.903–1.036 0.388 1.000 0.994–1.006 0.994
Daytime dozing 1.001 0.996–1.006 0.598 1.045 1.007–1.085 0.068 0.999 0.993–1.006 0.831
Nap during the day 0.995 0.989–1.001 0.088 1.012 0.964–1.063 0.648 0.998 0.991–1.005 0.552
Sleeplessness/insomnia Dialysis 0.485 0.055-4.28e + 00 0.514 0.681 446.026 1.721-1.156e + 05 0.041 0.555 0.032-9.433e + 00 0.684
Sleep duration 0.303 7.00e-02-1.31 0.11 0.681 0.009 2.49e-05-3.42 0.12 0.341 4.09e-02-2.85 0.32
Morning chronotype 0.619 0.279–1.373 0.238 0.681 0.354 0.053–2.374 0.288 0.287 0.092–0.888 0.03
Getting up in the morning 0.538 0.096–3.002 0.877 0.877 0.184 0.0003–99.841 0.601 0.554 0.055–5.534 0.615
Non-snoring 6.901 1.088e-01-4.376e + 02 0.362 0.681 17373.55 2.635e-05-8.304e + 12 0.349 11.224 1.239e-01-1.016e + 03 0.293
Daytime dozing 3.011 9.93e-02-91.304 0.527 0.681 0.0005 3.105e-11-7589.52 0.379 1.465 1.453e-02-147.69 0.871
Nap during the day 1.627 0.285–9.307 0.584 0.681 3.093 0.004-2428.268 0.741 1.558 0.154–15.719 0.707
Sleeplessness/insomnia Glomerular filtration rate -0.0007 -0.143-0.142 0.993 0.993 -0.227 -1.382-0.927 0.708 -0.008 -0.172-0.155 0.921
Sleep duration -0.018 -0.122-0.086 0.730 0.9765 0.123 -0.485-0.731 0.697 -0.058 -0.177-0.061 0.338
Morning chronotype -0.015 -0.064-0.033 0.542 0.9765 0.089 -0.144-0.322 0.460 -0.002 -0.063-0.059 0.954
Getting up in the morning 0.021 -0.093-0.136 0.715 0.9765 0.064 -0.497-0.624 0.827 0.053 -0.068-0.175 0.387
Non-snoring 0.232 0.017–0.447 0.034 0.119 -0.478 -2.435-1.478 0.643 0.239 0.001–0.478 0.049
Daytime dozing 0.023 -0.197-0.242 0.837 0.9765 -0.209 -1.772-1.353 0.799 -0.072 -0.285-0.142 0.489
Nap during the day -0.078 -0.149- -0.006 0.033 0.119 -0.055 -0.384-0.275 0.748 -0.077 -0.171-0.018 0.113
Open in a new tab

Fig. 2.

Fig. 2

Open in a new tab

Associations of genetic liability to 7 sleep traits with ESRD. Genetic liability to Non-snoring, getting up early, and insomnia was suggestively associated with ESRD in the primary analysis. Estimates are from the random-effects inverse variance weighted method

Fig. 3.

Fig. 3

Open in a new tab

Genetic liability to sleep traits in relation to end-stage renal disease

MR analysis for the association between sleep traits and other outcomes

Setting dialysis to the outcome, based on IVW analysis, revealed no evidence of a causal association between sleep duration (OR = 0.303, 95%CI 7.00E-2–1.31, P = 0.11, FDR = 0.681), sleeplessness/insomnia (OR = 0.485 95%CI 0.055-4.28e + 00, P = 0.514, FDR = 0.681), chronotype (OR = 0.619, 95%CI 0.279–1.373, P = 0.238, FDR = 0.681), getting up in the morning (OR = 0.538, 95%CI 0.096–3.002, P = 0.877, FDR = 0.877), non-snoring (OR = 6.901, 95%CI 1.088E-01-4.376E + 02, P = 0.362, FDR = 0.681), daytime dozing (OR = 3.011, 95%CI 9.93E-02-91.304, P = 0.527, FDR = 0.681), nap during the day (OR = 1.627, 95%CI 0.285–9.307, P = 0.584, FDR = 0.681) and dialysis.

In the analysis of the effect of sleep traits on glomerular filtration rate (GFR), there was no evidence of an effect of sleeplessness/ insomnia (b = -0.0007, 95%CI -0.143-0.142, P = 0.993, FDR = 0.993), sleep duration (b = -0.018, 95%CI-0.122-0.086, P = 0.730, FDR = 0.9765), chronotype (b = -0.015, 95%CI -0.064-0.033, P = 0.542, FDR = 0.9765), getting up in the morning (b = 0.021, 95%CI-0.093-0.136, P = 0.715, FDR = 0.9765), daytime dozing (b = 0.023, 95%CI -0.197-0.242, P = 0.837, FDR = 0.9765) on GFR based on the IVW method. There were suggestive evidence of effects of genetic liability to non-snoring (b = 0.232, 95%CI 0.017–0.447, P = 0.034, FDR = 0.119) and napping during the day (b = -0.078, 95%CI -0.149-0.006, P = 0.033, FDR = 0.119) on GFR.

Sensitivity analysis

In the sensitivity analysis, we conducted funnel pot, Cochran’s Q test, leave-one-out analysis, and MR-Egger intercept tests. The MR-Egger regression test revealed no horizontal pleiotropy for sleeplessness/insomnia (Intercept=-0.06, P = 0.4), sleep duration (Intercept = 0.021, P = 0.58), morning chronotype (Intercept=-0.024, P = 0.17), getting up easily in the morning (Intercept=-0.025, P = 0.38), non-snoring (Intercept = 0.089, P = 0.245), daytime dozing (Intercept= -0.053, P = 0.567), nap during the day (Intercept=-0.046, P = 0.204). The Cochran’s Q test revealed no heterogeneity in the IVW results for insomnia (Q = 21.32, P = 0.67), sleep duration (Q = 45.45, P = 0.256), morning chronotype (Q = 84.24, P = 0.268), getting up easily in the morning (Q = 20.28, P = 0.978), daytime dozing (Q = 12.62, P = 0.761), non-snoring (Q = 13.7, P = 0.85), daytime dozing (Q = 12.62, p = 0.761), nap during the day (Q = 24.68, P = 0.996). In addition, the MR-Egger regression test for the MR analysis of other outcomes revealed no horizontal pleiotropy and the Cochrane Q test revealed no heterogeneity (see Table 2). The leave-one-out analyses demonstrated the results’ consistency.

Table 2.

Sensitivity analysis of the causal association between sleep traits and the risk of ESRD.

Exposure Outcome MR-IVW MR-Egger MR-Egger intercept MR-PRESSO
Q Q_df Q_pval Q Q_df Q_pval Intercept SE P val Global test Pval
Sleeplessness/insomnia ESRD 21.32 25 0.67 20.6 24 0.662 -0.06 0.07 0.4 0.782
Sleep duration 45.45 40 0.256 45.09 39 0.232 0.021 0.037 0.58 0.334
Morning chronotype 84.24 77 0.268 82.17 76 0.294 -0.024 0.017 0.17 0.201
Getting up in the morning 20.28 35 0.978 19.49 34 0.978 -0.025 0.028 0.38 0.976
Non-snoring 13.7 20 0.85 12.27 19 0.874 0.089 0.07 0.245 0.813
Daytime dozing 12.62 17 0.761 12.28 16 0.724 -0.053 0.09 0.567 0.783
Nap during the day 24.68 46 0.996 23.02 45 0.997 -0.046 0.036 0.204 0.997
ESRD Sleeplessness/insomnia 18.72 19 0.475 18.56 18 0.419 -0.000575 0.00145 0.696 0.505
Sleep duration 13.977 19 0.785 13.689 18 0.749 -0.0008 0.0015 0.598 0.805
Morning chronotype 19.29 19 0.438 19.294 18 0.429 -0.0018 0.00198 0.367 0.378
Getting up in the morning 12.44 19 0.866 10.28 18 0.922 0.0023 0.0015 0.159 0.834
Non-snoring 32.58 19 0.027 29.83 18 0.039 0.0016 0.0012 0.214 0.616
Daytime dozing 16.24 19 0.641 16.15 18 0.582 -0.00028 0.00098 0.777 0.624
Nap during the day 24.69 19 0.17 18.97 18 0.335 -0.0026 0.0012 0.054 0.178
Sleeplessness/insomnia Dialysis 36.41 26 0.084 28.78 25 0.273 -0.094 0.036 0.016 0.822
Sleep duration 37.87 40 0.567 36.44 39 0.587 0.047 0.039 0.239 0.604
Morning chronotype 97.76 79 0.075 97.26 78 0.069 0.013 0.019 0.528 0.094
Getting up in the morning 46.09 36 0.120 45.93 35 0.102 0.016 0.045 0.729 0.128
Non-snoring 37.39 21 0.015 36.27 20 0.014 -0.068 0.086 0.441 0.605
Daytime dozing 9.74 18 0.939 8.63 17 0.951 0.075 0.071 0.306 0.935
Nap during the day 56.12 47 0.169 56.08 46 0.147 -0.0075 0.038 0.846 0.148
Sleeplessness/insomnia Glomerular filtration rate 15.37 10 0.119 15.12 9 0.088 0.0025 0.0065 0.706 0.103
Sleep duration 25.01 15 0.049 24.63 14 0.038 -0.0019 0.004 0.650 0.063
Morning chronotype 32.57 27 0.211 31.59 26 0.207 -0.0019 0.002 0.378 0.197
Getting up in the morning 30.22 15 0.011 30.169 14 0.007 -0.0006 0.0039 0.882 0.554
Non-snoring 18.68 10 0.044 17.67 9 0.039 0.0056 0.0079 0.492 0.054
Daytime dozing 19.15 9 0.023 18.94 8 0.015 0.0019 0.0063 0.775 0.317
Nap during the day 31.90 29 0.324 31.88 28 0.279 -0.00027 0.0019 0.888 0.368
Open in a new tab

ESRD, end-stage renal disease; OR, odds ratio; CI, confidence interval; IVW, inverse-variance weighted; FDR, P-value corrected for False Discovery Rate

Fig. 4.

Fig. 4

Open in a new tab

Forest plot (A), leave-one-out sensitivity analysis (B), scatter plot (C), and funnel plot (D) of the suggestive causal effect of getting up in the morning on ESRD risk

Reverse MR analysis

In assessing the influence of ESRD on the risk of sleep traits, the IVW technique revealed no evidence favouring a causal effect of ESRD on the risk of insomnia (OR = 0.997, 95%CI = 0.990–1.003, P = 0.324), getting up early (OR = 1.002, 95%CI 0.995–1.008, P = 0.616), non-snoring (OR = 1.002, 95%CI 0.995–1.010, P = 0.543), sleep duration (b = -0.001, 95%CI -0.008-0.006, P = 0.783), morning chronotype (OR = 0.994, 95%CI 0.986–1.003 P = 0.173), daytime napping (OR = 0.995, 95%CI 0.989–1.001 P = 0.088) or daytime dozing (OR = 1.001, 95%CI 0.996–1.006, P = 0.598). In the sensitivity analysis, the MR-Egger regression test revealed no horizontal pleiotropy and the Cochrane Q test revealed no heterogeneity (Table 2).

Multivariable MR analysis

Genetic liability to diabetes and BMI was significantly associated with ESRD (See Supplementary Tables 10, Additional File 1). In the multivariable MR adjusting for diabetes, there was no evidence for a causal association of genetic liability to sleeplessness/ insomnia, getting up early in the morning and non-snoring with ESRD. Likewise, after adjustment for BMI, associations between genetic liability to sleeplessness/ insomnia, getting up early in the morning, and non-snoring and ESRD did not persist (See Supplementary Tables 11, Additional File1).

In the multivariable MR analysis adjusting for depression, getting up early in the morning consistently showed a causality with ESRD (OR = 0.246, 95%CI 0.093–0.647, P = 0.0045, FDR = 0.0114), and the association between non-snoring and ESRD remained significant (OR = 0.034, 95%CI 0.0028–0.407, P = 0.0076, FDR = 0.0114). However, the causal association between sleeplessness/ insomnia and ESRD disappeared. After adjusting for hypertension, most associations between sleep traits and ESRD did not persist, but only the association between the genetic reliability to non-snoring and ESRD remained significant (OR = 0.038, 95%CI 0.0029–0.512, P = 0.0135, FDR = 0.0405) (See Supplementary Tables 11, Additional File 1).

Discussion

Principal findings

In this bidirectional TSMR investigation, sleeplessness/insomnia, waking up early, and not snoring were suggestively associated with the risk of ESRD. Furthermore, However, our data did not show evidence providing a causal connection between genetic predisposition to ESRD and sleep disturbances. Some of the associations remained after adjustment for depression and hypertension. Diabetes and BMI might partly mediate the link between sleep traits and ESRD.

Previous studies

Poor sleep quality and disruptions have been commonly observed in CKD and ESRD patients. A cross-sectional research indicated ESRD patients had higher sleep disturbances than CKD patients [29]. On the other hand, consistent with our findings, a recent observational research found that sleep disturbances were related to ESRD in patients with CKD [6] and that individuals with a healthy sleep pattern were associated with a substantial reduction in the risk of CKD [7].

In addition, we expanded these findings by demonstrating the effects of various sleep characteristics on ESRD. A Singapore Chinese Health Study found that both short and extended sleep durations were related to an increased risk of ESRD [30]. As for insomnia, a prospective cohort research revealed that nighttime insomnia is related to a modestly elevated risk of CKD [31], but a study reported that insomnia is not connected with the incidence of ESRD [32], which contradicts the present findings of MR analysis. There is a paucity of epidemiological research on healthy sleep habits, but a study indicated that a healthy lifestyle score system, which included a good sleep pattern, was connected with a reduced risk of CKD [33]. In addition, a study revealed that obstructive sleep apnea, the severity of which is related to snoring [34], contributed to the progression of CKD [35]. Although we identified a detrimental impact of insomnia on ESRD and that getting up in the morning and not snoring delayed disease development, there was inadequate previous evidence for causal associations between sleep traits and ESRD. Possible explanations include population differences, sample size, and inappropriate control of confounding variables.

According to research, sleep problems are linked to depression [36], which aligns with our discovery of a strong causal link between insomnia and depression. In addition, research suggested that depression may be a risk factor for the development of CKD [37]. This implied that sleep disturbance might affect ESRD through depression. The causal association between insomnia and ESRD attenuated after adjusting for depression, but the associations of non-snoring and getting up early in the morning with ESRD were even more robust in multivariable MR adjusting for depression, indicating that genetic correlations between these two sleep traits and depression are less likely to be a source of biassing these findings.

Additionally, consistent with our analysis of multivariable MR, sleep traits were shown to affect BMI [38], hypertension [39], and diabetes [40]. Several studies also linked BMI [41], hypertension [42], and type 2 diabetes [43] to ESRD. Specifically, our multivariable analysis linked sleep traits to obesity, hypertension, and an increased risk of diabetes. These factors may mediate the association between sleep traits and ESRD. After adjusting for these factors, most associations between sleep traits and ESRD did not persist, indicating that these factors might confound the observed associations between sleep traits and ESRD.

Potential mechanisms

The precise pathophysiological mechanisms behind the link between sleep traits and ESRD remain poorly known. In this and previous research, sleep characteristics were connected to obesity, hypertension, and diabetes, and ESRD may be triggered by obesity [44], high blood pressure [42], and diabetes [43, 45].

Sleep disorders were associated with a condition of the hypothalamic-pituitary-adrenal axis [46]; snoring associated with OSA was linked to impaired autonomic nervous function [47]. The higher risk of ESRD in patients with insomnia may be partially explained by sleep-induced alterations in the autonomic nervous system and hypothalamic-pituitary axis [48, 49]. Additionally, inflammation might change due to insomnia, primary snoring, and obstructive sleep apnea [50, 51]. At the same time, systemic and local chronic inflammation (in the kidney) operate as risk factors for diabetic renal disease and its development into ESRD [52].

Strengths and limitations

Our study has several strengths. This is the first MR analysis of sleep attributes with ESRD, probing evidence of the causal association between sleep-related characteristics and ESRD and studying the bidirectional causation relationship. Second, the MR design reduced the likelihood that confounding and other biases caused the observed bias. A large sample size and GWAS SNPs offered statistical validity for assessing causality. These steps improve conclusion validity.

Our study does, however, have certain shortcomings. First, participants in the ESRD where we obtained outcome data were Hispanic/Latino, while the exposure dataset we used was all European. A study showing genome-wide admixture mapping of CKD identified European ancestry-of-origin loci in Hispanic and Latino individuals, and the locus with European ancestry was associated with the CKD risk [53]. However, population stratification may contribute to confounders. The ancestry distribution, on the other hand, restricted the generalizability of our findings to other groups. Second, we could not determine if there were dose-response connections between sleep traits and ESRD. Still, uncertainty remains around the potential effects of public policy interventions on different sleep behaviors. Third, the findings of the Power analysis for non-snoring and getting up in the morning are minor, which might be due to the limited number of cases and sample size of ESRD. Finally, the results of the weighted median technique were not consistent with the suggestive associations provided by the IVW method in the primary MR analysis, indicating the presence of pleiotropy. Although we conducted sensitivity analyses that revealed no obvious pleiotropy, we find it difficult to verify the assumption that genetic instruments could only affect the outcome through the risk factor and not through pleiotropy.

Conclusions

Overall, our study of MR analysis had no strong evidence to support a protective or deleterious effect of genetically predicted sleep traits on ESRD nor strong evidence to support an effect of ESRD on sleep disorders. However, this study provides suggestive associations between getting up early, insomnia, and non-snoring with ESRD, and the necessity of further research into the mechanism behind the link between sleep disorders and ESRD is highlighted by this study.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1 (3.1MB, docx)

Acknowledgements

The NHGRI-EBI GWAS Catalog is funded by NHGRI Grant Number 2U41HG007823 and delivered by collaboration between the NHGRI, EMBL-EBI, and NCBI. We want to acknowledge the participants and investigators of the FinnGen study.

Abbreviations

CKD

Chronic kidney disease

ESRD

End-stage renal disease

MR

Mendelian randomization

TSMR

Two-sample mendelian randomization

BMI

Body mass index

GWAS

Genome-wide association study

OR

Odds ratio

CI

Confidence interval

IVs

Instrumental variables

SNPs

Single nucleotide polymorphisms

MR-PRESSO

MR-pleiotropy residual sum and outlier

FDR

False discovery rate

PVE

phenotypic variation explained

Author contribution

Y-ZB conceived and presented the idea. L-KX and Z-JX processed data and manuscript writing. Y-WJ participated in the acquisition and interpretation of data. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the Research Fund of Early Biological Markers of Geriatric Hyperalgesia and Early Identification Protocols for Multimorbidity Co-Morbidities in The Population (2020YFC2005002).

Data availability

GWAS summary statistics for sleep traits are publicly available through http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-of-phenotypes-for-337000-samples-in-the-uk-biobank. The summary statistics of GWAS for ESRD are derived from a GWAS conducted by Wojcik GL et al.(10.1038/s41586-019-1310-4). The data for dialysis is derived from https://www.finngen.fi/en. The summary data for the glomerular filtration rate is from a GWAS conducted by Pattaro C et al.( 10.1038/ncomms10023). In the assessment of risk factors, summary statistics for depression and hypertension are avalaible through https://www.finngen.fi/en. Summary statistics for body mass index (BMI) can be download from 10.7554/eLife.34408. The summary statistics of GWAS for diabetes are derived from a GWAS conducted by Xue A et al.( 10.1038/s41467-018-04951-w). All data can be downloaded from IEU OpenGWAS project (10.1101/2020.08.10.244293).

Declarations

Ethics approval and consent to participate

Not applicable. Ethical approval and informed consent for studies included in the analyses was provided in the original publications.

Consent for publication

Not applicable.

Conflict of interest

All authors declare no conflict of interest.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72. doi: 10.1016/S0140-6736(13)60687-X. [DOI] [PubMed] [Google Scholar]
  • 2.Johansen KL, Chertow GM, Gilbertson DT, et al. Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2022;79(4 Suppl 1):A8–a12. US Renal Data System 2021 Annual Data Report. [DOI] [PMC free article] [PubMed]
  • 3.Kastarinen M, Juutilainen A, Kastarinen H, et al. Risk factors for end-stage renal disease in a community-based population: 26-year follow-up of 25,821 men and women in eastern finland. J Intern Med. 2010;267(6):612–20. doi: 10.1111/j.1365-2796.2009.02197.x. [DOI] [PubMed] [Google Scholar]
  • 4.Tan L, Chen P, Chiang H, et al. Insomnia and poor sleep in CKD: a systematic review and Meta-analysis. Kidney Med. 2022;4(5):100458. doi: 10.1016/j.xkme.2022.100458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007;14(1):82–99. doi: 10.1053/j.ackd.2006.10.001. [DOI] [PubMed] [Google Scholar]
  • 6.Yamamoto R, Shinzawa M, Isaka Y, et al. Sleep Quality and Sleep Duration with CKD are Associated with Progression to ESKD. Clin J Am Soc Nephrology: CJASN. 2018;13(12):1825–32. doi: 10.2215/CJN.01340118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Zhang H, Wang B, Chen C, et al. Sleep patterns, genetic susceptibility, and incident chronic kidney disease: a prospective study of 370 671 participants. Front Neurosci. 2022;16:725478. doi: 10.3389/fnins.2022.725478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Wu Y, Zhai L, Zhang D. Sleep duration and obesity among adults: a meta-analysis of prospective studies. Sleep Med. 2014;15(12):1456–62. doi: 10.1016/j.sleep.2014.07.018. [DOI] [PubMed] [Google Scholar]
  • 9.Thomson CA, Morrow KL, Flatt SW, et al. Relationship between sleep quality and quantity and weight loss in women participating in a weight-loss intervention trial. Obes (Silver Spring) 2012;20(7):1419–25. doi: 10.1038/oby.2012.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Xi B, He D, Zhang M, et al. Short sleep duration predicts risk of metabolic syndrome: a systematic review and meta-analysis. Sleep Med Rev. 2014;18(4):293–7. doi: 10.1016/j.smrv.2013.06.001. [DOI] [PubMed] [Google Scholar]
  • 11.Shan Z, Ma H, Xie M, et al. Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care. 2015;38(3):529–37. doi: 10.2337/dc14-2073. [DOI] [PubMed] [Google Scholar]
  • 12.Wang Y, Mei H, Jiang YR, et al. Relationship between duration of sleep and hypertension in adults: a Meta-analysis. J Clin Sleep Med. 2015;11(9):1047–56. doi: 10.5664/jcsm.5024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Larsson SC, Markus HS. Genetic liability to Insomnia and Cardiovascular Disease Risk. Circulation. 2019;140(9):796–8. doi: 10.1161/CIRCULATIONAHA.119.041830. [DOI] [PubMed] [Google Scholar]
  • 14.Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89–98. doi: 10.1093/hmg/ddu328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife. 2018;7:e34408. doi: 10.7554/eLife.34408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Verbanck M, Chen C-Y, Neale B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–8. doi: 10.1038/s41588-018-0099-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of Observational Studies in Epidemiology using mendelian randomization: the STROBE-MR Statement. JAMA. 2021;326(16):1614–21. doi: 10.1001/jama.2021.18236. [DOI] [PubMed] [Google Scholar]
  • 18.Elsworth B, Lyon M, Alexander T et al.The MRC IEU OpenGWAS data infrastructure. BioRxiv 2020
  • 19.Neale B. RAPID GWAS OF THOUSANDS OF PHENOTYPES FOR 337,000 SAMPLES IN THE UK BIOBANK. http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-of-phenotypes-for-337000-samples-in-the-uk-biobank
  • 20.Wojcik GL, Graff M, Nishimura KK, et al. Genetic analyses of diverse populations improves discovery for complex traits. Nature. 2019;570(7762):514–8. doi: 10.1038/s41586-019-1310-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Pattaro C, Teumer A, Gorski M, et al. Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nat Commun. 2016;7:10023. doi: 10.1038/ncomms10023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kurki MI, Karjalainen J, Palta P et al. FinnGen: Unique genetic insights from combining isolated population and national health register data. medRxiv 2022:2022.2003.2003.22271360
  • 23.Xue A, Wu Y, Zhu Z, et al. Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. Nat Commun. 2018;9(1):2941. doi: 10.1038/s41467-018-04951-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Vaucher J, Keating B, Lasserre A, et al. Cannabis use and risk of schizophrenia: a mendelian randomization study. Mol Psychiatry. 2018;23(5):1287–92. doi: 10.1038/mp.2016.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol) 1995;57(1):289–300. [Google Scholar]
  • 26.Greco MF, Minelli C, Sheehan NA, et al. Detecting pleiotropy in mendelian randomisation studies with summary data and a continuous outcome. Stat Med. 2015;34(21):2926–40. doi: 10.1002/sim.6522. [DOI] [PubMed] [Google Scholar]
  • 27.Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–25. doi: 10.1093/ije/dyv080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Sanderson E. Multivariable Mendelian Randomization and Mediation. Cold Spring Harb Perspect Med 2021;11(2) [DOI] [PMC free article] [PubMed]
  • 29.Mujahid M, Nasir K, Qureshi R, et al. Comparison of the quality of sleep in patients with chronic kidney Disease and End-Stage Renal Disease. Cureus. 2022;14(4):e23862. doi: 10.7759/cureus.23862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Geng T, Jafar T, Yuan J, et al. Sleep duration and risk of end-stage renal disease: the Singapore Chinese Health Study. Sleep Med. 2019;54:22–7. doi: 10.1016/j.sleep.2018.10.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Sasaki S, Yoshioka E, Saijo Y, et al. A prospective cohort study of insomnia and chronic kidney disease in japanese workers. Sleep Breath. 2018;22(1):257–65. doi: 10.1007/s11325-017-1508-3. [DOI] [PubMed] [Google Scholar]
  • 32.Lu J, Freire A, Molnar M et al. ,. Association of Chronic Insomnia With Mortality and Adverse Renal Outcomes. Mayo Clinic proceedings 2018;93(11):1563–1570 [DOI] [PubMed]
  • 33.Luo W, Gong L, Chen X, et al. Lifestyle and chronic kidney disease: a machine learning modeling study. Front Nutr. 2022;9:918576. doi: 10.3389/fnut.2022.918576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Alshaer H, Hummel R, Mendelson M, et al. Objective relationship between sleep apnea and frequency of snoring assessed by machine learning. J Clin sleep medicine: JCSM : official publication Am Acad Sleep Med. 2019;15(3):463–70. doi: 10.5664/jcsm.7676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Umbro I, Fabiani V, Fabiani M, et al. A systematic review on the association between obstructive sleep apnea and chronic kidney disease. Sleep Med Rev. 2020;53:101337. doi: 10.1016/j.smrv.2020.101337. [DOI] [PubMed] [Google Scholar]
  • 36.Cai L, Bao Y, Fu X, et al. Causal links between major depressive disorder and insomnia: a mendelian randomisation study. Gene. 2021;768:145271. doi: 10.1016/j.gene.2020.145271. [DOI] [PubMed] [Google Scholar]
  • 37.Horiba Y, Ishizawa K, Takasaki K, et al. Effect of depression on progression to end-stage renal disease or pre-end-stage renal disease death in advanced diabetic nephropathy: a prospective cohort study of the diabetes study from the Center of Tokyo Women’s Medical University. J diabetes Invest. 2022;13(1):94–101. doi: 10.1111/jdi.13620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Vigoureux T, Lee S, Buxton O, et al. Stressor reactivity to insufficient sleep and its association with body mass index in middle-aged workers. J Sleep Res. 2020;29(6):e12955. doi: 10.1111/jsr.12955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Manolis T, Manolis A, Apostolopoulos E, et al. Cardiovascular Complications of Sleep Disorders: a Better Night’s Sleep for a healthier heart / from bench to Bedside. Curr Vasc Pharmacol. 2021;19(2):210–32. doi: 10.2174/1570161118666200325102411. [DOI] [PubMed] [Google Scholar]
  • 40.Schipper S, Van Veen M, Elders P, et al. Sleep disorders in people with type 2 diabetes and associated health outcomes: a review of the literature. Diabetologia. 2021;64(11):2367–77. doi: 10.1007/s00125-021-05541-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Lew Q, Jafar T, Talaei M, et al. Increased body mass index is a risk factor for end-stage renal disease in the chinese Singapore population. Kidney Int. 2017;92(4):979–87. doi: 10.1016/j.kint.2017.03.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Reynolds K, Gu D, Muntner P, et al. A population-based, prospective study of blood pressure and risk for end-stage renal disease in China. J Am Soc Nephrol. 2007;18(6):1928–35. doi: 10.1681/ASN.2006111199. [DOI] [PubMed] [Google Scholar]
  • 43.Shen Y, Cai R, Sun J, et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine. 2017;55(1):66–76. doi: 10.1007/s12020-016-1014-6. [DOI] [PubMed] [Google Scholar]
  • 44.Funes D, Blanco D, Hong L, et al. Prevalence of chronic kidney disease and end-stage renal disease in a bariatric versus nonbariatric population: a retrospective analysis of the U.S. National Inpatient Sample database. Surg Obes Relat diseases: official J Am Soc Bariatr Surg. 2022;18(2):281–7. doi: 10.1016/j.soard.2021.09.021. [DOI] [PubMed] [Google Scholar]
  • 45.Zou Y, Zhao L, Zhang J, et al. Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease. Ren Fail. 2022;44(1):562–70. doi: 10.1080/0886022X.2022.2056053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Bezerra M, Rodrigues R, Souza R. The hypothalamic-pituitary-adrenal axis and the central monoaminergic systems: a pathophysiological link to insomnia with clinical implications. Sleep Sci (Sao Paulo Brazil) 2022;15(1):128–35. doi: 10.5935/1984-0063.20220032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Wu Y, Tian L, Ma D, et al. Autonomic nervous function and low-grade inflammation in children with sleep-disordered breathing. Pediatr Res. 2022;91(7):1834–40. doi: 10.1038/s41390-021-01691-4. [DOI] [PubMed] [Google Scholar]
  • 48.Soomro Q, Charytan D. Cardiovascular autonomic nervous system dysfunction in chronic kidney disease and end-stage kidney disease: disruption of the complementary forces. Curr Opin Nephrol Hypertens. 2021;30(2):198–207. doi: 10.1097/MNH.0000000000000686. [DOI] [PubMed] [Google Scholar]
  • 49.Meuwese C, Carrero J. Chronic kidney disease and hypothalamic-pituitary axis dysfunction: the chicken or the egg? Arch Med Res. 2013;44(8):591–600. doi: 10.1016/j.arcmed.2013.10.009. [DOI] [PubMed] [Google Scholar]
  • 50.Fernandez-Mendoza J, Baker J, Vgontzas A, et al. Insomnia symptoms with objective short sleep duration are associated with systemic inflammation in adolescents. Brain Behav Immun. 2017;61:110–6. doi: 10.1016/j.bbi.2016.12.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Jahn C, Gouveris H, Matthias C. Systemic inflammation in patients with compromised upper airway anatomy and primary snoring or mild obstructive sleep apnea. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the german society for Oto-Rhino-Laryngology. Head and Neck Surgery. 2016;273(10):3429–33. doi: 10.1007/s00405-016-4103-5. [DOI] [PubMed] [Google Scholar]
  • 52.Gusev E, Solomatina L, Zhuravleva Y et al. The Pathogenesis of End-Stage Renal Disease from the Standpoint of the Theory of General Pathological Processes of Inflammation. International journal of molecular sciences 2021;22(21) [DOI] [PMC free article] [PubMed]
  • 53.Horimoto A, Xue D, Cai J, et al. Genome-wide admixture mapping of estimated glomerular filtration rate and chronic kidney Disease identifies european and african ancestry-of-origin loci in hispanic and latino individuals in the United States. J Am Soc Nephrology: JASN. 2022;33(1):77–87. doi: 10.1681/ASN.2021050617. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material 1 (3.1MB, docx)

Data Availability Statement

GWAS summary statistics for sleep traits are publicly available through http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-of-phenotypes-for-337000-samples-in-the-uk-biobank. The summary statistics of GWAS for ESRD are derived from a GWAS conducted by Wojcik GL et al.(10.1038/s41586-019-1310-4). The data for dialysis is derived from https://www.finngen.fi/en. The summary data for the glomerular filtration rate is from a GWAS conducted by Pattaro C et al.( 10.1038/ncomms10023). In the assessment of risk factors, summary statistics for depression and hypertension are avalaible through https://www.finngen.fi/en. Summary statistics for body mass index (BMI) can be download from 10.7554/eLife.34408. The summary statistics of GWAS for diabetes are derived from a GWAS conducted by Xue A et al.( 10.1038/s41467-018-04951-w). All data can be downloaded from IEU OpenGWAS project (10.1101/2020.08.10.244293).

Articles from BMC Medical Genomics are provided here courtesy of BMC

RESOURCES